Flagship Pioneering, a company that conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability, has recognised Nancy Simonian, MD, CEO of Syros Pharmaceuticals (NASDAQ: SYRS), with the 2019 Pioneering Leader Award, it was reported yesterday.
Simonian joined Syros Pharmaceuticals as its founding CEO in 2012 and it is claimed that she has led its transformation from a discovery-stage company with a pioneering platform into a publicly traded clinical-stage company with multiple product candidates.
Noubar Afeyan, PhD, founder and CEO of Flagship Pioneering, said, 'Leveraging her successful and distinguished career in bringing new medicines to patients, Nancy has charted the course for Syros, built an impressive team, and positioned the company to deliver new therapies addressing cancer and monogenic diseases. During her tenure at Syros, Nancy has raised capital both privately and in the public markets to support new options for patients and create value for shareholders. In each step of Syros' journey, Nancy has shown pioneering spirit, strong instincts, and true leadership. We congratulate Nancy and look forward to Syros' bright future.'
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis